PLAGL2‐EGFR‐HIF‐1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity-Reference-Cited by-同舟云学术

PLAGL2‐EGFR‐HIF‐1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity

Published:2021-02 Issue:2 Volume:73 Page:674-691
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Hu Weiwei¹,Zheng Shufang¹,Guo Haixin¹,Dai Beiying¹,Ni Jiaping¹,Shi Yaohong¹,Bian Hanrui¹,Li Lanxin¹,Shen Yumeng¹,Wu Mo¹,Tian Zhoutong¹,Liu Guilai¹,Hossain Md Amir¹,Yang Hongbao¹,Wang Duowei¹,Zhang Qin²,Yu Jun²,Birnbaumer Lutz³,Feng Jifeng²,Yu Decai⁴,Yang Yong¹

Affiliation:

1. Center for New Drug Safety Evaluation and Research State Key Laboratory of Natural Medicines China Pharmaceutical University Nanjing China

2. Department of Chemotherapy Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University Nanjing China

3. Institute of Biomedical Research Catholic University of Argentina Buenos Aires Argentina

4. Department of general Surgery Affiliated Drum Tower Hospital Medical School of Nanjing University Nanjing China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31293

Reference45 articles.

1. Erratum: Advances in targeted therapies for hepatocellular carcinoma in the genomic era